Physician profile
Alexander Kaplan
NPI 1679673933
$7,309.90
in general payments reported to CMS, 2019-2025
24 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $626 · 2021: $862 · 2022: $1,185 · 2023: $960 · 2024: $1,038 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,242.04 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $820.65 | 2019-2025 | Opsumit |
| Merck Sharp & Dohme LLC | $778.80 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $720.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.88 | 2019-2022 | |
| Pfizer INC. | $584.25 | 2019-2025 | |
| Edwards Lifesciences Corporation | $512.23 | 2019-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $351.04 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $345.27 | 2019-2024 | Xarelto |
| Abbott Laboratories | $245.28 | 2019-2022 | |
| Amarin Pharma, INC. | $177.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $162.70 | 2022-2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $148.14 | 2020-2021 | |
| Novo Nordisk INC | $101.21 | 2021-2025 | Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $79.45 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $66.45 | 2021-2023 | Nexletol |
| Bridgebio Pharma, INC. | $60.48 | 2025 | Attruby |
| Gilead Sciences, INC. | $54.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $54.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.98 | 2021 | |
| Scpharmaceuticals INC. | $41.13 | 2023-2024 | |
| Medicomp INC | $40.89 | 2025 | Telepatch Cardiac Monitor |
| Bardy Diagnostics, INC. | $24.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.